Gabriela Morales-Rivera

Ms. Morales-Rivera’s recent client representations include the following:

General Corporate Counseling and Significant Transactions

• Akero Therapeutics in connection with:
  • its $65 million Series A financing
  • its $70 million Series B financing
  • its $105.8 million initial public offering
• Allovir in its $120 million Series B financing 
• Aptinyx in connection with:
  • its $65 million Series A financing
  • its $70 million Series B financing
  • its $117.8 million initial public offering
• ElevateBio in its $150 million Series A financing
• Exosome Diagnostics in connection with:
  • its $30 million Series C financing
  • its sale to Bio-Techne Corporation
• Kymera Therapeutics in connection with:
  • its $30 million Series A financing
  • its $65 million Series B financing
  • its research and development collaboration with Vertex Pharmaceuticals
• Neon Therapeutics in connection with:
  • its $106 million Series B financing
  • its $100 million initial public offering
• Nimbus Therapeutics in connection with:
  • the $1.2 billion sale of its ACC inhibitor program to Gilead Bioscience
  • its multi-target strategic alliance with Celgene Corporation in immunology
  • its $65 million Series 2018 preferred stock financing
• Relay Therapeutics in connection with:
  • its $63 million Series B financing
  • its $400 million Series C financing
• SmileDirectClub in its $380 million financing
• Tango Therapeutics in its $55 million Series A financing

Public Company Representation and Capital Markets Transactions

• Intellia Therapeutics in its $150.0 million follow-on offering
• Sage Therapeutics in its $575 million and $345 million follow-on offering
• Repligen Corp. in connection with:
  • its acquisition of TangenX Technology Corporation
  • its acquisition of Spectrum, Inc.
  • its $138 million follow-on offering
• resTORbio in connection with:
  • its $97.8 million initial public offering
  • its $50.0 million follow-on offering